Compagnie Lombard Odier SCmA’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,500	Closed	-$5K	–	753
2017 Q2	$5K	Hold	1,500	–	–	﹤0.01%	681
2017 Q1	$14K	Hold	1,500	–	–	﹤0.01%	660
2016 Q4	$12K	Hold	1,500	–	–	﹤0.01%	747
2016 Q3	$17K	Hold	1,500	–	–	﹤0.01%	804
2016 Q2	$18K	Hold	1,500	–	–	﹤0.01%	791
2016 Q1	$15K	Hold	1,500	–	–	﹤0.01%	852
2015 Q4	$34K	Hold	1,500	–	–	﹤0.01%	741
2015 Q3	$25K	Hold	1,500	–	–	﹤0.01%	677
2015 Q2	$34K	Hold	1,500	–	–	﹤0.01%	669
2015 Q1	$39K	Hold	1,500	–	–	﹤0.01%	806
2014 Q4	$33K	Hold	1,500	–	–	﹤0.01%	660
2014 Q3	$28K	Hold	1,500	–	–	﹤0.01%	769
2014 Q2	$35K	Hold	1,500	–	–	﹤0.01%	777
2014 Q1	$50K	Hold	1,500	–	–	﹤0.01%	724
2013 Q4	$44K	Buy	+1,500	New	+$27.5K	﹤0.01%	721

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Compagnie Lombard Odier SCmA's OMED Position: Q3 2017 in Review

Compagnie Lombard Odier SCmA sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2017, closing a stake of 1,500 shares — an estimated $5K sold.

Compagnie Lombard Odier SCmA first reported a position in OMED in Q4 2013 and held it in 15 quarters. The position peaked at $50K in Q1 2014. 58 funds tracked by Wall St. Rank hold OMED as of Q3 2017.

Compagnie Lombard Odier SCmA reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 1,500 OncoMed Pharmaceuticals, Inc. shares in Q3 2017, an estimated $5K.
Compagnie Lombard Odier SCmA first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2013 and held it in 15 quarters.
Compagnie Lombard Odier SCmA's OncoMed Pharmaceuticals, Inc. position peaked at $50K in Q1 2014.
58 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2017, filed 14 Nov 2017.